Details for New Drug Application (NDA): 209597

NDA 209597 describes CHOLESTYRAMINE, which is a drug marketed by Ajanta Pharma Ltd, Alkem Labs Ltd, Ani Pharms, Endo Operations, Epic Pharma Llc, Ivax Sub Teva Pharms, Tagi, Teva, Upsher Smith Labs, Zydus Pharms, Macleods Pharms Ltd, and Teva Pharms, and is included in eighteen NDAs. It is available from twelve suppliers. Additional details are available on the CHOLESTYRAMINE profile page.

The generic ingredient in CHOLESTYRAMINE is cholestyramine. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the cholestyramine profile page.

Summary for 209597

Tradename:	CHOLESTYRAMINE
Applicant:	Tagi
Ingredient:	cholestyramine
Patents:	0

Pharmacology for NDA: 209597

Mechanism of Action

Bile-acid Binding Activity

Suppliers and Packaging for NDA: 209597

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
CHOLESTYRAMINE	cholestyramine	POWDER;ORAL	209597	ANDA	TAGI Pharma, Inc.	51224-011	51224-011-10	348.6 g in 1 CAN (51224-011-10)
CHOLESTYRAMINE	cholestyramine	POWDER;ORAL	209597	ANDA	TAGI Pharma, Inc.	51224-011	51224-011-20	60 POUCH in 1 CARTON (51224-011-20) / 8.3 g in 1 POUCH

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;ORAL			Strength	EQ 4GM RESIN/PACKET
Approval Date:	Mar 9, 2021	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;ORAL			Strength	EQ 4GM RESIN/SCOOPFUL
Approval Date:	Mar 9, 2021	TE:	AB	RLD:	No

Complete Access Available with Subscription